MX2021011491A - Polvos secos inhalables. - Google Patents

Polvos secos inhalables.

Info

Publication number
MX2021011491A
MX2021011491A MX2021011491A MX2021011491A MX2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A
Authority
MX
Mexico
Prior art keywords
inhalable dry
dry powders
dry powder
inhalable
cannabinoids
Prior art date
Application number
MX2021011491A
Other languages
English (en)
Spanish (es)
Inventor
Chad C Smutney
Joseph J Guarneri
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MX2021011491A publication Critical patent/MX2021011491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021011491A 2019-03-22 2020-03-20 Polvos secos inhalables. MX2021011491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962822303P 2019-03-22 2019-03-22
PCT/US2020/023977 WO2020198051A1 (en) 2019-03-22 2020-03-20 Inhalable dry powders

Publications (1)

Publication Number Publication Date
MX2021011491A true MX2021011491A (es) 2022-01-18

Family

ID=72608595

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021011491A MX2021011491A (es) 2019-03-22 2020-03-20 Polvos secos inhalables.
MX2025008306A MX2025008306A (es) 2019-03-22 2021-09-21 Polvos secos inhalables

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025008306A MX2025008306A (es) 2019-03-22 2021-09-21 Polvos secos inhalables

Country Status (6)

Country Link
US (1) US20220241271A1 (https=)
EP (1) EP3941438A4 (https=)
JP (2) JP2022527054A (https=)
CA (1) CA3133804A1 (https=)
MX (2) MX2021011491A (https=)
WO (1) WO2020198051A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3171220A1 (en) * 2020-03-19 2021-09-23 Glenn MATTES Dried particle inhalation for delivery of cannabis
US20240050450A1 (en) * 2020-10-16 2024-02-15 Michael Ogburn Inhalable Cannabinoid Formulations
KR20240093906A (ko) * 2021-10-27 2024-06-24 맨카인드 코포레이션 폐고혈압을 치료하기 위한 방법 및 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017152D1 (de) * 1999-08-25 2005-02-03 Advanced Inhalation Res Inc Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
KR101644250B1 (ko) * 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
IN2015DN00888A (https=) * 2006-02-22 2015-07-10 Mannkind Corp
ES2929343T3 (es) * 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
PE20181295A1 (es) * 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
CA3012679C (en) * 2016-01-29 2023-12-12 Mannkind Corporation Dry powder inhaler

Also Published As

Publication number Publication date
EP3941438A4 (en) 2022-09-21
JP2022527054A (ja) 2022-05-30
US20220241271A1 (en) 2022-08-04
CA3133804A1 (en) 2020-10-01
JP2025061049A (ja) 2025-04-10
WO2020198051A1 (en) 2020-10-01
EP3941438A1 (en) 2022-01-26
MX2025008306A (es) 2025-08-01

Similar Documents

Publication Publication Date Title
MX2018009159A (es) Inhalador de polvo seco.
MX2021011491A (es) Polvos secos inhalables.
CR6937A (es) Nuevo polvo inhalable conteniendo tiotropium
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
ECSP034571A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
UY28271A1 (es) Compuestos químicos
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2022009231A (es) Inhalador de polvo seco y metodo de uso.
AR108231A1 (es) Composiciones farmacéuticas orales de mesalazina
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
MX2021007177A (es) Formulacion de inhalacion de polvo seco y su uso para el tratamiento terapeutico de los pulmones.
UY28589A1 (es) Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen
MX2023011701A (es) Composicion farmaceutica para liberacion controlada de treprostinil.